JP2017516785A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017516785A5 JP2017516785A5 JP2016569636A JP2016569636A JP2017516785A5 JP 2017516785 A5 JP2017516785 A5 JP 2017516785A5 JP 2016569636 A JP2016569636 A JP 2016569636A JP 2016569636 A JP2016569636 A JP 2016569636A JP 2017516785 A5 JP2017516785 A5 JP 2017516785A5
- Authority
- JP
- Japan
- Prior art keywords
- disease
- cancer
- salt according
- autoimmune
- carcinoma
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN2597/CHE/2014 | 2014-05-27 | ||
| IN2596/CHE/2014 | 2014-05-27 | ||
| IN2596CH2014 | 2014-05-27 | ||
| IN2597CH2014 | 2014-05-27 | ||
| PCT/IB2015/053940 WO2015181728A1 (en) | 2014-05-27 | 2015-05-26 | Improved forms of a pi3k delta selective inhibitor for use in pharmaceutical formulations |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020088147A Division JP2020122022A (ja) | 2014-05-27 | 2020-05-20 | 医薬製剤用ｐｉ３ｋデルタ選択的抑制剤の改良形態 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017516785A JP2017516785A (ja) | 2017-06-22 |
| JP2017516785A5 true JP2017516785A5 (enExample) | 2017-08-03 |
| JP6987501B2 JP6987501B2 (ja) | 2022-01-05 |
Family
ID=53499042
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016569636A Expired - Fee Related JP6987501B2 (ja) | 2014-05-27 | 2015-05-26 | 医薬製剤用ｐｉ３ｋデルタ選択的抑制剤の改良形態 |
| JP2020088147A Pending JP2020122022A (ja) | 2014-05-27 | 2020-05-20 | 医薬製剤用ｐｉ３ｋデルタ選択的抑制剤の改良形態 |
| JP2022062937A Pending JP2022082680A (ja) | 2014-05-27 | 2022-04-05 | 医薬製剤用ｐｉ３ｋデルタ選択的抑制剤の改良形態 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020088147A Pending JP2020122022A (ja) | 2014-05-27 | 2020-05-20 | 医薬製剤用ｐｉ３ｋデルタ選択的抑制剤の改良形態 |
| JP2022062937A Pending JP2022082680A (ja) | 2014-05-27 | 2022-04-05 | 医薬製剤用ｐｉ３ｋデルタ選択的抑制剤の改良形態 |
Country Status (22)
| Country | Link |
|---|---|
| US (4) | US9969740B2 (enExample) |
| EP (2) | EP3971188A1 (enExample) |
| JP (3) | JP6987501B2 (enExample) |
| KR (1) | KR20170007480A (enExample) |
| CN (2) | CN106661030B (enExample) |
| AU (1) | AU2015265542B2 (enExample) |
| BR (1) | BR112016027674A2 (enExample) |
| CA (1) | CA2949932C (enExample) |
| CY (1) | CY1124316T1 (enExample) |
| DK (1) | DK3149000T3 (enExample) |
| EA (1) | EA032506B1 (enExample) |
| ES (1) | ES2880999T3 (enExample) |
| HR (1) | HRP20211151T1 (enExample) |
| HU (1) | HUE054916T2 (enExample) |
| IL (1) | IL249058B2 (enExample) |
| LT (1) | LT3149000T (enExample) |
| PL (1) | PL3149000T3 (enExample) |
| PT (1) | PT3149000T (enExample) |
| RS (1) | RS62136B1 (enExample) |
| SI (1) | SI3149000T1 (enExample) |
| SM (1) | SMT202100532T1 (enExample) |
| WO (1) | WO2015181728A1 (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT3149000T (pt) * | 2014-05-27 | 2021-07-27 | Rhizen Pharmaceuticals S A | Sal tosilato cristalino de um inibidor seletivo de pi3k delta para uso em formulações farmacêuticas |
| CA3024123A1 (en) | 2016-05-27 | 2017-11-30 | Tg Therapeutics, Inc. | Combination of anti-cd20 antibody, p13 kinase-delta selective inhibitor, and btk inhibitor to treat b-cell proliferative disorders |
| BR112019004185A2 (pt) | 2016-09-09 | 2019-09-03 | Lab Francais Du Fractionnement | combinação de um anticorpo anti-cd20, inibidor de pi3-quinase-delta inibidor e anticorpo anti-pd-1 ou anti-pd-l1 para tratamento de cânceres hematológicos |
| CA3146785A1 (en) * | 2019-07-15 | 2021-01-21 | Johnson Matthey Public Limited Company | Amorphous umbralisib monotosylate |
| US20220143026A1 (en) | 2020-11-12 | 2022-05-12 | Tg Therapeutics, Inc. | Triple combination to treat b-cell malignancies |
| US11807689B1 (en) | 2022-06-01 | 2023-11-07 | Tg Therapeutics, Inc. | Anti-CD20 antibody compositions |
| US11965032B1 (en) | 2022-06-01 | 2024-04-23 | Tg Therapeutics, Inc. | Anti-CD20 antibody compositions |
| US11884740B1 (en) | 2022-06-01 | 2024-01-30 | Tg Therapeutics, Inc. | Anti-CD20 antibody compositions |
| US11814439B1 (en) | 2022-06-01 | 2023-11-14 | Tg Therapeutics, Inc. | Anti-CD20 antibody compositions |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1278748B1 (en) | 2000-04-25 | 2011-03-23 | ICOS Corporation | Inhibitors of human phosphatidyl-inositol 3-kinase delta |
| BRPI0316779B1 (pt) | 2002-12-16 | 2020-04-28 | Genentech Inc | anticorpo humanizado que liga cd20 humano, composição, artigo manufaturado, método de indução da apoptose, método de tratamento de câncer cd20 positivo, métodos de tratamento de doenças autoimunes, ácidos nucléicos isolados, vetores de expressão, células hospedeiras, método para a produção de um anticorpo 2h7 humanizado, polipeptídeo isolado, formulação líquida, método de tratamento de artrite reumatóide (ra) e anticorpos de ligação de cd20 humanizados |
| WO2005016348A1 (en) | 2003-08-14 | 2005-02-24 | Icos Corporation | Method of inhibiting immune responses stimulated by an endogenous factor |
| US20100202963A1 (en) | 2008-11-13 | 2010-08-12 | Gallatin W Michael | Therapies for hematologic malignancies |
| CN102439012A (zh) | 2009-03-24 | 2012-05-02 | 吉里德卡利斯托加公司 | 2-嘌呤基-3-甲苯基-喹唑啉酮衍生物的阻转异构体和使用方法 |
| CA2759724A1 (en) | 2009-04-20 | 2010-10-28 | Calistoga Pharmaceuticals, Inc. | Methods of treatment for solid tumors |
| JP6181173B2 (ja) * | 2012-07-04 | 2017-08-16 | ライゼン・ファーマシューティカルズ・エスアー | 選択的ｐｉ３ｋデルタ阻害剤 |
| PT3149000T (pt) * | 2014-05-27 | 2021-07-27 | Rhizen Pharmaceuticals S A | Sal tosilato cristalino de um inibidor seletivo de pi3k delta para uso em formulações farmacêuticas |
-
2015
- 2015-05-26 PT PT157335324T patent/PT3149000T/pt unknown
- 2015-05-26 RS RS20210920A patent/RS62136B1/sr unknown
- 2015-05-26 US US15/313,454 patent/US9969740B2/en active Active
- 2015-05-26 EP EP21182208.5A patent/EP3971188A1/en not_active Withdrawn
- 2015-05-26 AU AU2015265542A patent/AU2015265542B2/en not_active Ceased
- 2015-05-26 SI SI201531656T patent/SI3149000T1/sl unknown
- 2015-05-26 EA EA201692255A patent/EA032506B1/ru unknown
- 2015-05-26 KR KR1020167036318A patent/KR20170007480A/ko not_active Ceased
- 2015-05-26 WO PCT/IB2015/053940 patent/WO2015181728A1/en not_active Ceased
- 2015-05-26 CN CN201580034288.7A patent/CN106661030B/zh not_active Expired - Fee Related
- 2015-05-26 ES ES15733532T patent/ES2880999T3/es active Active
- 2015-05-26 DK DK15733532.4T patent/DK3149000T3/da active
- 2015-05-26 HR HRP20211151TT patent/HRP20211151T1/hr unknown
- 2015-05-26 SM SM20210532T patent/SMT202100532T1/it unknown
- 2015-05-26 PL PL15733532T patent/PL3149000T3/pl unknown
- 2015-05-26 LT LTEPPCT/IB2015/053940T patent/LT3149000T/lt unknown
- 2015-05-26 CN CN202010471226.5A patent/CN111635406A/zh active Pending
- 2015-05-26 JP JP2016569636A patent/JP6987501B2/ja not_active Expired - Fee Related
- 2015-05-26 CA CA2949932A patent/CA2949932C/en active Active
- 2015-05-26 BR BR112016027674A patent/BR112016027674A2/pt not_active Application Discontinuation
- 2015-05-26 HU HUE15733532A patent/HUE054916T2/hu unknown
- 2015-05-26 EP EP15733532.4A patent/EP3149000B1/en active Active
-
2016
- 2016-11-20 IL IL249058A patent/IL249058B2/en unknown
-
2018
- 2018-04-11 US US15/950,606 patent/US10414773B2/en active Active
-
2019
- 2019-08-30 US US16/557,091 patent/US10947244B2/en not_active Expired - Fee Related
-
2020
- 2020-05-20 JP JP2020088147A patent/JP2020122022A/ja active Pending
- 2020-12-23 US US17/247,806 patent/US20210269446A1/en not_active Abandoned
-
2021
- 2021-07-21 CY CY20211100652T patent/CY1124316T1/el unknown
-
2022
- 2022-04-05 JP JP2022062937A patent/JP2022082680A/ja active Pending